- Companies
- SiBionics
SiBionics Valuation, Funding & Investors
SiBionics is valued at $717M as of December 2022.
Last SiBionics valuation
$717M
Series D · Dec 2022
Last SiBionics funding round
$72M
Series D · Dec 2022
Cumulative funding SiBionics raised
$226M
across 3 funding rounds
Key investors in SiBionics
HSG
Source Code Capital
Green Pine Capital Partners
Qianhai Fund of Funds
CPE
EFung Capital
About SiBionics
SiBionics is a Chinese medical device company developing AI-based devices for chronic disease management, including its GS1 and GS3 continuous glucose monitoring (CGM) systems for people with diabetes. Its GS3 sensor is described as the world's thinnest CGM and has earned CE Mark approval alongside other products in its lineup, placing the company in the competitive global CGM market alongside established international players.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$717M (Dec 2022)
SiBionics Valuation
SiBionics is currently valued at $717M, based on its Series D in December 2022.
The $72M round was led by Shanghai Biomedical Industrial Equity Investment Fund, with participation from Industrial Securities Capital and China New Town Dev.
SiBionics valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Dec 2022 | Series D | $717M |
SiBionics Funding History
SiBionics has raised a total of $226M across 3 funding rounds.
SiBionics' first fundraising round was a $28M Series B in April 2020. The most recent completed round was a $72M Series D in December 2022.
SiBionics funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Dec 2022 | Series D | Shanghai Biomedical Industrial Equity Investment Fund (lead); Industrial Securities Capital; China New Town Dev | $72M | $717M | SiBionics (硅基仿生), a Chinese medical device company, specializes in AI-based devices for chronic disease management, including its GS1 continuous glucose monitoring (CGM) system, which received CE Mark approval. On December 21, 2022, it announced a Series D funding round raising nearly CNY 500 million (approximately $71.7-73.7 million), jointly led by Shanghai Healthcare Capital (also referred to as Shanghai Biomedical Industrial Equity Investment Fund) and Guangdong Chinese Medicine Healthcare Capital, with participation from Industrial Securities Capital, Next Capital, China New Town Development, and others. Optimas Capital served as the financial advisor. The proceeds are designated for R&D of new products, expansion of automatic production lines, and business development in domestic and international markets. This round aligns with investor interest in healthcare innovations, particularly in medtech for conditions like diabetes, as evidenced by SiBionics' CGM advancements. The funding reflects growing investment in China's medical device sector amid advancements in wearable diagnostics. SiBionics positions itself in the competitive CGM market, competing with global players while expanding regulatory approvals like the CE Mark. |
| Jan 2022 | Series C | China Life Investment Holding (lead); CPE (lead); Fortune Capital; RiverHead Capital; JD Investments; Cedarlake Capital; Lucion; C&D Emerging Investment; Jingming Capital; Qianhai Fund of Funds; Source Code Capital | $126M | - | SiBionics is a digital health company developing continuous glucose monitoring (CGM) systems, including the GS3 described as the world's thinnest CGM which earned CE mark. SiBionics operates in the competitive CGM market, focusing on innovative sensors for diabetes management. Recent developments include product unveilings and regulatory approvals like the CE mark for GS3. The company has raised a total of $150.31M across 7 funding rounds with 23 investors. A Series C - III round occurred on January 21, 2022, with lead investors including China Life Investment Holding and CPE alongside others like C&D Emerging Investment, Cedarlake Capital, Fortune Capital, JD Investments, Jingming Capital, Lucion, Qianhai Fund of Funds, RiverHead Capital, and Source Code Capital. The subsequent Series D round on November 22, 2022, raised $71.61M (reported as ~$72M in some summaries) from investors including Kaiheng Private Fund, Shanghai Biomedical Industry Equity Investment Fund Management, China New Town Development, Industrial Securities Capital, and Next Capital. The company's funding trajectory shows growth from earlier rounds (Series B in 2017, multiple Series C stages) to later-stage D, indicating scaling efforts in R&D, manufacturing, and market expansion. |
| Apr 2020 | Series B | China SDIC Gaoxin (lead); EFung Capital; Green Pine Capital Partners; HSG | $28M | - | - |
Who has invested in SiBionics?
18 investors have backed SiBionics across its funding rounds, including HSG, Source Code Capital, Green Pine Capital Partners, Qianhai Fund of Funds, CPE and EFung Capital.
Lead investors include Shanghai Biomedical Industrial Equity Investment Fund, China Life Investment Holding, CPE and China SDIC Gaoxin.
SiBionics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 1 | Participant | Jan 2022 | ||
| 1 | Participant | Jan 2022 | ||
| 1 | Lead | Jan 2022 | ||
| -- | 1 | Participant | Jan 2022 | |
| 1 | Participant | Jan 2022 | ||
| 1 | Participant | Apr 2020 | ||
| 1 | Participant | Jan 2022 | ||
| 1 | Participant | Jan 2022 | ||
| 1 | Participant | Dec 2022 | ||
| 1 | Participant | Jan 2022 | ||
| 1 | Lead | Apr 2020 | ||
| 1 | Lead | Dec 2022 | ||
| 1 | Participant | Apr 2020 | ||
This data is available for Pro users. Sign up to see all 18 SiBionics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialSiBionics Competitors
SiBionics competitors include listed companies like UltraGreen.ai and Wandong Medical, and private ones like Carestream, Scivita Medical Technology, Petmate and Embark.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $800M | - | ||
| Publicly listed | $138M | $78M | $672M | 2.9x | ||
| Private | - | - | $1.1B | - | ||
| Private | - | - | $420M | - | ||
| Publicly listed | $201M | ($46M) | $1B | 3.2x | ||
| Private | - | - | $700M | - |
SiBionics Public Comps
SiBionics is still privately-owned, but its public comps include Mesa Laboratories, Japan Lifeline, Star Sports Medicine, Beijing Deep Glint Tech, Barco, Diagnósticos da América, Shenzhen Sunwin, MiMedx Group, Cytek Biosciences and QuidelOrtho.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $249M | $46M | 3.3x | 3.3x | 18.0x | 13.2x | |||
| $381M | $89M | 1.8x | 1.7x | 7.5x | 7.7x | |||
| $60M | $24M | 9.0x | - | 22.0x | - | |||
| $23M | ($29M) | 25.1x | 8.7x | (19.8x) | (80.2x) | |||
| $1.1B | $141M | 0.7x | 0.6x | 5.2x | 5.3x | |||
| $2.2B | $346M | 0.9x | 1.0x | 5.6x | 4.9x | |||
| $20M | ($147M) | 37.7x | - | (5.0x) | - | |||
| $419M | $78M | 1.4x | 1.8x | 7.2x | 21.0x | |||
This data is available for Pro users. Sign up to see all SiBionics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about SiBionics
| When was SiBionics founded? | SiBionics was founded in 2015. |
| Where is SiBionics headquartered? | SiBionics is headquartered in China. |
| Is SiBionics publicly listed? | No, SiBionics is a private, VC-backed company. |
| What is SiBionics' valuation? | SiBionics was last valued at $717M in its Series D in December 2022. |
| How much funding has SiBionics raised? | SiBionics has raised $226M across 3 funding rounds. |
| What was SiBionics' last funding round? | SiBionics' last funding round was a $72M Series D in December 2022, led by Shanghai Biomedical Industrial Equity Investment Fund. |
| Who are SiBionics' investors? | SiBionics' investors include Fortune Capital, RiverHead Capital, CPE, JD Investments, Cedarlake Capital, EFung Capital, Lucion, C&D Emerging Investment, Industrial Securities Capital, Jingming Capital and 8 others. |
| Which companies are comparable to SiBionics? | Companies comparable to SiBionics include Carestream, UltraGreen.ai, Scivita Medical Technology, Petmate, Wandong Medical and Embark. |
See companies similar to SiBionics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




